PharmGKB: Very important pharmacogene - HMGCR

Pharmacogenetics and Genomics

Volumn 21, Issue 2, 2011, Pages 98-101

  Medina, Marisa Wong ^a   Sangkuhl, Katrin ^b   Klein, Teri E ^b   Altman, Russ B ^b,c  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHOLESTEROL SYNTHESIS; CHROMOSOME 5Q; DRUG EFFICACY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; HAPLOTYPE; HUMAN; INSULIN RESISTANCE; KIDNEY GRAFT; OVARY POLYCYSTIC DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CLINICAL TRIALS AS TOPIC; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA-REDUCTASES, NADP-DEPENDENT; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS;

EID: 78751618475     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328336c81b     Document Type: Article

References (18)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
2. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14:37-44.
3. Lindgren V, Luskey KL, Russell DW, Francke U. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci USA 1985; 82:8567-8571.
4. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003; 302:2141-2144.
5. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 2008; 28:2078-2084.
6. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008; 118:355-362.
7. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291:2821-2827.
8. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117: 1537-1544.
9. Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008; 18:1021-1026.
10. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5:352-358.
11. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet 2009; 2:173-181.
12. Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 2007; 48:2072-2078.
13. Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008; 200:109-114.
14. Xu N, Taylor KD, Azziz R, Goodarzi MO. Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. Fertil Steril 2009.
15. Poduri A, Khullar M, Bahl A, Sharma YP, Talwar KK. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol 2009; 28:451-460.
16. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358:1240-1249.
17. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40:189-197.
18. Chen YC, Chen YD, Li X, Post W, Herrington D, Polak JF, et al. The HMG- CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis. Lipids 2009; 44:733-743.